Full text is available at the source.
Abstract
GLP-1 receptor agonist (liraglutide) was evaluated for safety and effectiveness in adolescents with obesity.
- Pediatric obesity is associated with numerous metabolic complications.
- Treatment options for obesity in adolescents are currently limited.
- The evaluation focused on liraglutide’s performance in a clinical setting in Taiwan.
- Initial findings suggest liraglutide may have potential benefits for this population.
Simplified